Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Trasylol aprotinin regulatory update

BAY and FDA issued a "Dear Healthcare Professional" letter after the investigator-sponsored BART trial was stopped because of higher mortality among cardiac surgery

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE